PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
October 21, 2010European Heart Journal1,818 citationsOpen Access

Lipoprotein(a) as a cardiovascular risk factor: current status

View Full Paper
BNBørge G. NordestgaardMCM. John ChapmanKRKausik K. Ray

Key Points

Key points are not available for this paper at this time.

Abstract

We recommend screening for elevated Lp(a) in those at intermediate or high CVD/CHD risk, a desirable level <50 mg/dL as a function of global cardiovascular risk, and use of niacin for Lp(a) and CVD/CHD risk reduction.

Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

Nordestgaard et al. (2010) studied this question.

synapsesocial.com/papers/69d56dd375589c71d767d0ffhttps://doi.org/10.1093/eurheartj/ehq386
Ask AI
Helpful
Bookmark
Share
View Full Paper

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Association of Mutations in the Apolipoprotein B Gene with Hypercholesterolemia and the Risk of Ischemic Heart Disease1998 · 194 citations
  2. 2Recommendations for the use of LDL apheresis2008 · 272 citations
  3. 3Fifteen year mortality in Coronary Drug Project patients: Long-term benefit with niacin1986 · 1,842 citations
  4. 4Extreme Lipoprotein(a) Levels and Risk of Myocardial Infarction in the General Population2007 · 552 citations
  5. 5Genetic Variants Associated with Lp(a) Lipoprotein Level and Coronary Disease2009 · 1,682 citations